Advertisement

Miscellaneous Manifestations of Behçet Syndrome

  • Johannes NowatzkyEmail author
  • İzzet Fresko
Chapter

Abstract

Behçet syndrome (BS) may rarely present with rapidly progressive hearing loss, epididymitis, or orchitis. Fever can occur in BS with neurologic, vascular, or arthritic involvement, but is not a typical finding in their absence. Data for a direct association of BS with malignancy remain difficult to interpret, but several, especially hematologic malignancies and hematinic deficiencies can mimic BS. There is general consensus that manifestations such as hearing loss and epididymitis are part of the BS disease spectrum, but there remains controversy regarding others, such as renal disease. Within those areas of controversy, it is debatable whether a proposed manifestation represents a true association, is part of the BS disease spectrum, or is an independent primary disease mimicking BS. Thorough familiarity with the clinical phenotypes of BS, including its rarer manifestations, is a prerequisite for the successful evaluation of patients with suspected BS, especially if their presentation includes manifestations that lie at the far ends or outside of the recognized Behçet disease spectrum.

Keywords

Amyloidosis Bladder Epididymitis Glomerulonephritis Impotence Myelodysplastic Vestibular 

References

  1. 1.
    Zhou Q, Wang H, Schwartz DM, Stoffels M, Park YH, Zhang Y, et al. Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease. Nat Genet. 2016;48(1):67–73.CrossRefGoogle Scholar
  2. 2.
    Aeschlimann FA, Batu ED, Canna SW, Go E, Gul A, Hoffmann P, et al. A20 haploinsufficiency (HA20): clinical phenotypes and disease course of patients with a newly recognised NF-kB-mediated autoinflammatory disease. Ann Rheum Dis. 2018;77(5):728–35.CrossRefGoogle Scholar
  3. 3.
    Kadowaki T, Ohnishi H, Kawamoto N, Hori T, Nishimura K, Kobayashi C, et al. Haploinsufficiency of A20 causes autoinflammatory and autoimmune disorders. J Allergy Clin Immunol. 2018;141(4):1485–8 e11.PubMedCrossRefGoogle Scholar
  4. 4.
    Seyahi E, Karaaslan H, Ugurlu S, Yazici H. Fever in Behçet’s syndrome. Clin Exp Rheumatol. 2013;31(3 Suppl 77):64–7.PubMedGoogle Scholar
  5. 5.
    Aeschlimann FA, Batu ED, Canna SW, Go E, Hoffmann P, Leavis HL, Gül A, et al. A20 haploinsufficiency (HA20): clinical phenotypes and disease course of patients with a newly recognised NF-kB-mediated autoinflammatory disease. Ann Rheum Dis. 2018;77:728–35.CrossRefGoogle Scholar
  6. 6.
    Esatoglu SN, Hatemi G, Salihoglu A, Hatemi I, Soysal T, Celik AF. A reappraisal of the association between Behçet’s disease, myelodysplastic syndrome and the presence of trisomy 8: a systematic literature review. Clin Exp Rheumatol. 2015;33(6 Suppl 94):S145–51.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Lee KY, Kim DY, Chang JY, Bang D. Two cases of acute leukopenia induced by colchicine with concurrent immunosuppressants use in Behcet’s disease. Yonsei Med J. 2008;49(1):171–3.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Rosenthal NS, Farhi DC. Myelodysplastic syndromes and acute myeloid leukemia in connective tissue disease after single-agent chemotherapy. Am J Clin Pathol. 1996;106(5):676–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Demiroglu H, Dundar S. Behcet’s disease and neutropenia. Int J Dermatol. 1997;36(7):557–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Rogers RS. Recurrent aphthous stomatitis: clinical characteristics and associated systemic disorders. Semin Cutan Med Surg. 1997;16(4):278–83.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Leiferman KM, O’Duffy JD, Perry HO, Greipp PR, Giuliani ER, Gleich GJ. Recurrent incapacitating mucosal ulcerations. A prodrome of the hypereosinophilic syndrome. JAMA. 1982;247(7):1018–20.PubMedCrossRefGoogle Scholar
  12. 12.
    Budak-Alpdogan T, Demircay Z, Alpdogan O, et al. Behçet’s disease in patients with chronic myelogenous leukemia: possible role of interferon-alpha treatment in the occurrence of Behçet’s symptoms. Ann Hematol. 1997;74(1):45–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Segawa F, Shimizu Y, Saito E, Kinoshita M. Behçet’s disease induced by interferon therapy for chronic myelogenous leukemia. J Rheumatol. 1995;22(6):1183–4.PubMedGoogle Scholar
  14. 14.
    Budak-Alpdogan T, Demirçay AO, Direskeneli H, Ergun T, Oztürk A, et al. Skin hyperreactivity of Behçet’s patients (pathergy reaction) is also positive in interferon alpha-treated chronic myeloid leukaemia patients, indicating similarly altered neutrophil functions in both disorders. Br J Rheumatol. 1998;37(11):1148–51.PubMedCrossRefGoogle Scholar
  15. 15.
    Karincaoglu Y, Kaya E, Esrefoglu M, Aydogdu I. Development of large genital ulcer due to hydroxyurea treatment in a patient with chronic myeloid leukemia and Behcet’s disease. Leuk Lymphoma. 2003;44(6):1063–5.PubMedCrossRefGoogle Scholar
  16. 16.
    Vaiopoulos G, Terpos E, Viniou N, Nodaros K, Rombos J, Loukopoulos D. Behcet’s disease in a patient with chronic myelogenous leukemia under hydroxyurea treatment: a case report and review of the literature. Am J Hematol. 2001;66(1):57–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Cakmak SK, Gül U, Kiliç A, Gönül M, Soylu S, Demirel O. Behçet’s disease associated with chronic myelogenous leukemia and chronic graft-vs-host disease. Leuk Lymphoma. 2006;47(12):2674–5.PubMedCrossRefGoogle Scholar
  18. 18.
    Barreyro L, Chlon TM, Starczynowski DT. Chronic immune response dysregulation in MDS pathogenesis. Blood. 2018;132(15):1553–60.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Gangat N, Patnaik MM, Tefferi A. Myelodysplastic syndromes: contemporary review and how we treat. Am J Hematol. 2016;91(1):76–89.PubMedCrossRefGoogle Scholar
  20. 20.
    Ivy KS, Brent Ferrell P Jr. Disordered immune regulation and its therapeutic targeting in myelodysplastic syndromes. Curr Hematol Malig Rep. 2018;13(4):244–55.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Sperling AS, Gibson CJ, Ebert BL. The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia. Nat Rev Cancer. 2017;17(1):5–19.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Wang C, Yang Y, Gao S, Chen J, Yu J, Zhang H, et al. Immune dysregulation in myelodysplastic syndrome: clinical features, pathogenesis and therapeutic strategies. Crit Rev Oncol Hematol. 2018;122:123–32.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Braun T, Fenaux P. Myelodysplastic Syndromes (MDS) and autoimmune disorders (AD): cause or consequence? Best Pract Res Clin Haematol. 2013;26(4):327–36.PubMedCrossRefPubMedCentralGoogle Scholar
  24. 24.
    Shimanovsky A, Alvarez Argote J, Murali S, Dasanu CA. Autoimmune manifestations in patients with multiple myeloma and monoclonal gammopathy of undetermined significance. BBA Clin. 2016;6:12–8.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Mekinian A, Grignano E, Braun T, Decaux O, Liozon E, Costedoat-Chalumeau N, et al. Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study. Rheumatology (Oxford). 2016;55(2):291–300.CrossRefGoogle Scholar
  26. 26.
    Komrokji RS, Kulasekararaj A, Al Ali NH, Kordasti S, Bart-Smith E, Craig BM, et al. Autoimmune diseases and myelodysplastic syndromes. Am J Hematol. 2016;91(5):E280–3.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Shen Y, Ma HF, Luo D, Cai JF, Zou J, Guan JL. High incidence of gastrointestinal ulceration and cytogenetic aberration of trisomy 8 as typical features of Behcet’s disease associated with myelodysplastic syndrome: a series of 16 consecutive Chinese patients from the Shanghai Behcet’s disease database and comparison with the literature. Biomed Res Int. 2018;2018:8535091.PubMedPubMedCentralGoogle Scholar
  28. 28.
    Tada Y, Koarada S, Haruta Y, Mitamura M, Ohta A, Nagasawa K. The association of Behçet’s disease with myelodysplastic syndrome in Japan: a review of the literature. Clin Exp Rheumatol. 2006;24(5 Suppl 42):S115–9.PubMedPubMedCentralGoogle Scholar
  29. 29.
    Eder L, Rozenbaum M, Boulman N, Aayubkhanov E, Wolfovitz E, Zisman D, et al. Behçet’s disease, myelodysplastic syndrome, trisomy 8, gastroenterological involvement--an association. Clin Exp Rheumatol. 2005;23(4 Suppl 38):S91–5.PubMedGoogle Scholar
  30. 30.
    Tascilar K, Melikoglu M, Ugurlu S, Sut N, Caglar E, Yazici H. Vascular involvement in Behcet’s syndrome: a retrospective analysis of associations and the time course. Rheumatology (Oxford). 2014;53(11):2018–22.CrossRefGoogle Scholar
  31. 31.
    Wang S, Broder N, Marchetta P, Nowatzky J. Myelodysplastic syndrome presenting as a Behcet’s-like disease with aortitis. BMJ Case Rep. 2018;2018.Google Scholar
  32. 32.
    Ahn JK, Cha HS, Koh EM, Kim SH, Kim YG, Lee CK, et al. Behcet’s disease associated with bone marrow failure in Korean patients: clinical characteristics and the association of intestinal ulceration and trisomy 8. Rheumatology (Oxford). 2008;47(8):1228–30.CrossRefGoogle Scholar
  33. 33.
    Fine LA, Hoffman LD, Hoffman MD. Aphthous ulcerations associated with trisomy 8-positive myelodysplastic syndrome. J Am Acad Dermatol. 2007;57(2 Suppl):S38–41.PubMedCrossRefGoogle Scholar
  34. 34.
    Lin YC, Liang TH, Chang HN, Lin JS, Lin HY. Behcet disease associated with myelodysplastic syndrome. J Clin Rheumatol. 2008;14(3):169–74.PubMedCrossRefGoogle Scholar
  35. 35.
    Kimura S, Kuroda J, Akaogi T, Hayashi H, Kobayashi Y, Kondo M. Trisomy 8 involved in myelodysplastic syndromes as a risk factor for intestinal ulcers and thrombosis--Behçet’s syndrome. Leuk Lymphoma. 2001;42(1–2):115–21.PubMedCrossRefGoogle Scholar
  36. 36.
    Toyonaga T, Nakase H, Matsuura M, Minami N, Yamada S, Honzawa Y, et al. Refractoriness of intestinal Behçet’s disease with myelodysplastic syndrome involving trisomy 8 to medical therapies - our case experience and review of the literature. Digestion. 2013;88(4):217–21.PubMedCrossRefGoogle Scholar
  37. 37.
    Sloand EM, Wu CO, Greenberg P, Young N, Barrett J. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol. 2008;26(15):2505–11.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Becker K, Fitzgerald O, Green AJ, Keogan M, Newbury-Ecob R, Greenhalgh L, et al. Constitutional trisomy 8 and Behçet syndrome. Am J Med Genet A. 2009;149A(5):982–6.PubMedCrossRefGoogle Scholar
  39. 39.
    Kawabata H, Sawaki T, Kawanami T, Shimoyama K, Karasawa H, Fukushima T, et al. Myelodysplastic syndrome complicated with inflammatory intestinal ulcers: significance of trisomy 8. Intern Med. 2006;45(22):1309–14.PubMedCrossRefGoogle Scholar
  40. 40.
    Ohno E, Ohtsuka E, Watanabe K, Kohno T, Takeoka K, Saburi Y, et al. Behçet’s disease associated with myelodysplastic syndromes. A case report and a review of the literature. Cancer. 1997;79(2):262–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Giannouli S, Voulgarelis M, Zintzaras E, Tzioufas AG, Moutsopoulos HM. Autoimmune phenomena in myelodysplastic syndromes: a 4-yr prospective study. Rheumatology (Oxford). 2004;43(5):626–32.CrossRefGoogle Scholar
  42. 42.
    Lee SJ, Park JK, Lee EY, Joo SH, Jung KC, Lee EB, et al. Certain autoimmune manifestations are associated with distinctive karyotypes and outcomes in patients with myelodysplastic syndrome: a retrospective Cohort Study. Medicine. 2016;95(13):e3091.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Nonami A, Takenaka K, Sumida C, Aizawa K, Kamezaki K, Miyamoto T, et al. Successful treatment of myelodysplastic syndrome (MDS)-related intestinal Behçet’s disease by up-front cord blood transplantation. Intern Med. 2007;46(20):1753–6.PubMedCrossRefGoogle Scholar
  44. 44.
    Tomonari A, Tojo A, Takahashi T, Iseki T, Ooi J, Takahashi S, et al. Resolution of Behçet’s disease after HLA-mismatched unrelated cord blood transplantation for myelodysplastic syndrome. Ann Hematol. 2004;83(7):464–6.PubMedCrossRefGoogle Scholar
  45. 45.
    Yamato K. Successful cord blood stem cell transplantation for myelodysplastic syndrome with Behcet disease. Int J Hematol. 2003;77(1):82–5.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Bangerter M, Griesshammer MV, Tirpitz C, Krauter J, Heil G, Hafner M, et al. Myelodysplastic syndrome with monosomy 7 after immunosuppressive therapy in Behçet’s disease. Scand J Rheumatol. 1999;28(2):117–9.PubMedCrossRefGoogle Scholar
  47. 47.
    Michels SD, McKenna RW, Arthur DC, Brunning RD. Therapy-related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphologic study of 65 cases. Blood. 1985;65(6):1364–72.PubMedCrossRefGoogle Scholar
  48. 48.
    Fraison J-B, Mekinian A, Grignano E, Kahn J-E, Arlet J-B, Decaux O, et al. Efficacy of Azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Res. 2016;43:13–7.PubMedCrossRefGoogle Scholar
  49. 49.
    Grignano E, Jachiet V, Fenaux P, Ades L, Fain O, Mekinian A. Autoimmune manifestations associated with myelodysplastic syndromes. Ann Hematol. 2018;97(11):2015–23.PubMedCrossRefGoogle Scholar
  50. 50.
    Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10(3):223–32.PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    Costa R, Abdulhaq H, Haq B, Shadduck RK, Latsko J, Zenati M, et al. Activity of azacitidine in chronic myelomonocytic leukemia. Cancer. 2011;117(12):2690–6.PubMedCrossRefGoogle Scholar
  52. 52.
    Fianchi L, Criscuolo M, Breccia M, Maurillo L, Salvi F, Musto P, et al. High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study. Leuk Lymphoma. 2013;54(3):658–61.PubMedCrossRefGoogle Scholar
  53. 53.
    Kaklamani VG, Tzonou A, Kaklamanis PG. Behçet’s disease associated with malignancies. Report of two cases and review of the literature. Clin Exp Rheumatol. 2005;23(4 Suppl 38):S35–41.PubMedGoogle Scholar
  54. 54.
    Ahn JK, Oh JM, Lee J, Koh E-M, Cha H-S. Behcet’s disease associated with malignancy in Korea: a single center experience. Rheumatol Int. 2010;30(6):831–5.PubMedCrossRefGoogle Scholar
  55. 55.
    Lin Y, Li G, Zheng W, Tian X, Zhang F. Behcet’s disease associated with malignancy: a report of 41 Chinese cases. Int J Rheum Dis. 2014;17(4):459–65.PubMedCrossRefGoogle Scholar
  56. 56.
    Na SY, Shin J, Lee E-S. Morbidity of solid cancer in Behςet’s disease: analysis of 11 cases in a series of 506 patients. Yonsei Med J. 2013;54(4):895–901.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Jung YS, Han M, Kim DY, Cheon JH, Park S. Cancer risk in Korean patients with Behcet’s disease: a nationwide population-based study. PLoS One. 2017;12(12):e0190182.PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Wang L-H, Wang W-M, Hsu S-M, Lin S-H, Shieh C-C. Risk of overall and site-specific cancers in Behçet disease: a nationwide population-based study in Taiwan. J Rheumatol. 2015;42(5):879–84.PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    Calabrese LH, Calabrese C, Cappelli LC. Rheumatic immune-related adverse events from cancer immunotherapy. Nat Rev Rheumatol. 2018;14(10):569–79.PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–68.PubMedCrossRefPubMedCentralGoogle Scholar
  61. 61.
    Dalvin LA, Shields CL, Orloff M, Sato T, Shields JA. CHECKPOINT INHIBITOR IMMUNE THERAPY: systemic indications and ophthalmic side effects. Retina. 2018;38(6):1063–78.PubMedCrossRefPubMedCentralGoogle Scholar
  62. 62.
    Sun MM, Levinson RD, Filipowicz A, Anesi S, Kaplan H, Wang W, et al. Uveitis in patients treated with CTLA-4 and PD-1 checkpoint blockade inhibition. Ocul Immunol Inflamm. 2019:1–11.Google Scholar
  63. 63.
    Abdel-Wahab N, Shah M, Lopez-Olivo MA, Suarez-Almazor ME. Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review. Ann Intern Med. 2018;168(2):121–30.PubMedCrossRefGoogle Scholar
  64. 64.
    Pedersen M, Andersen R, Nørgaard P, Jacobsen S, Thielsen P, Thor Straten P, et al. Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease. Cancer Immunol Immunother. 2014;63(12):1341–6.PubMedCrossRefGoogle Scholar
  65. 65.
    Sonbay ND, Saka C, Tatlican S, Vuralkan E, Aygener N, Eren C, et al. Audiological evaluation in patients with Behcet’s disease. J Laryngol Otol. 2014;128(8):694–7.PubMedCrossRefGoogle Scholar
  66. 66.
    Sota J, Vitale A, Orlando I, Lopalco G, Franceschini R, Fabiani C, et al. Auditory involvement in Behcet’s disease: relationship with demographic, clinical, and therapeutic characteristics. Clin Rheumatol. 2017;36(2):445–9.PubMedCrossRefGoogle Scholar
  67. 67.
    Adler YD, Jovanovic S, Jivanjee A, Krause L, Zouboulis CC. Adamantiades-Behçet’s disease with inner ear involvement. Clin Exp Rheumatol. 2002;20(4 Suppl 26):S40–2.PubMedGoogle Scholar
  68. 68.
    Mancini P, Atturo F, Di Mario A, Portanova G, Ralli M, De Virgilio A, et al. Hearing loss in autoimmune disorders: prevalence and therapeutic options. Autoimmun Rev. 2018;17(7):644–52.PubMedCrossRefGoogle Scholar
  69. 69.
    Marsili M, Marzetti V, Lucantoni M, Lapergola G, Gattorno M, Chiarelli F, et al. Autoimmune sensorineural hearing loss as presenting manifestation of paediatric Behçet disease responding to adalimumab: a case report. Ital J Pediatr. 2016;42(1):81.PubMedPubMedCentralCrossRefGoogle Scholar
  70. 70.
    Narvaez J, Valverde-Garcia J, Alegre-Sancho JJ, Juanola X, Clavaguera MT, Roig-Escofet D. Sudden cochlear hearing loss in a patient with Behcet’s disease. Rev Rhum Engl Ed. 1998;65(1):63–4.PubMedGoogle Scholar
  71. 71.
    Gemignani G, Berrettini S, Bruschini P, Sellari-Franceschini S, Fusari P, Piragine F, et al. Hearing and vestibular disturbances in Behçet’s syndrome. Ann Otol Rhinol Laryngol. 1991;100(6):459–63.PubMedCrossRefGoogle Scholar
  72. 72.
    Kulahli I, Balci K, Koseoglu E, Yuce I, Cagli S, Senturk M. Audio-vestibular disturbances in Behcet’s patients: report of 62 cases. Hear Res. 2005;203(1–2):28–31.PubMedCrossRefGoogle Scholar
  73. 73.
    Smith LN. Unilateral sensorineural hearing loss in Behcet’s disease. Am J Otolaryngol. 1994;15(4):286–8.PubMedCrossRefGoogle Scholar
  74. 74.
    Choung Y-H, Cho MJ, Park K, Choi SJ, Shin YR, Lee E-S. Audio-vestibular disturbance in patients with Behçet’s disease. Laryngoscope. 2006;116(11):1987–90.PubMedCrossRefPubMedCentralGoogle Scholar
  75. 75.
    Ak E, Harputluoglu U, Oghan F, Baykal B. Behçet’s disease and hearing loss. Auris Nasus Larynx. 2004;31(1):29–33.PubMedCrossRefPubMedCentralGoogle Scholar
  76. 76.
    Bakhshaee M, Mahdi B, Ghasemi MM, Mehdi GM, Hatef MR, Reza HM, et al. Hearing loss in Behçet syndrome. Otolaryngol Head Neck Surg. 2007;137(3):439–42.PubMedCrossRefPubMedCentralGoogle Scholar
  77. 77.
    Bayazit YA, Yilmaz M, Gunduz B, Altinyay S, Kemaloglu YK, Onder M, et al. Distortion product otoacoustic emission findings in Behcet’s disease and rheumatoid arthritis. ORL J Otorhinolaryngol Relat Spec. 2007;69(4):233–8.PubMedCrossRefPubMedCentralGoogle Scholar
  78. 78.
    Dagli M, Eryilmaz A, Tanrikulu S, Aydin A, Gonul M, Gul U, et al. Evaluation of cochlear involvement by distortion product otoacoustic emission in Behçet’s disease. Auris Nasus Larynx. 2008;35(3):333–7.PubMedCrossRefPubMedCentralGoogle Scholar
  79. 79.
    Muluk NB, Birol A. Effects of Behçet’s disease on hearing thresholds and transient evoked otoacoustic emissions. J Otolaryngol. 2007;36(4):220–6.PubMedCrossRefPubMedCentralGoogle Scholar
  80. 80.
    Pollak L, Luxon LM, Haskard DO. Labyrinthine involvement in Behçet’s syndrome. J Laryngol Otol. 2001;115(7):522–9.PubMedCrossRefGoogle Scholar
  81. 81.
    Igarashi Y, Watanabe Y, Aso S. A case of Behçet’s disease with otologic symptoms. ORL J Otorhinolaryngol Relat Spec. 1994;56(5):295–8.PubMedCrossRefGoogle Scholar
  82. 82.
    Brama I, Fainaru M. Inner ear involvement in Behçet’s disease. Arch Otolaryngol. 1980;106(4):215–7.PubMedCrossRefGoogle Scholar
  83. 83.
    Evereklioglu C, Cokkeser Y, Doganay S, Er H, Kizilay A. Audio-vestibular evaluation in patients with Behçet’s syndrome. J Laryngol Otol. 2001;115(9):704–8.PubMedCrossRefGoogle Scholar
  84. 84.
    Soylu L, Aydoğan B, Soylu M, Ozsahinoğlu C. Hearing loss in Behçet’s disease. Ann Otol Rhinol Laryngol. 1995;104(11):864–7.PubMedCrossRefGoogle Scholar
  85. 85.
    Süslü AE, Polat M, Köybaşi S, Biçer YO, Funda YO, Parlak AH. Inner ear involvement in Behçet’s disease. Auris Nasus Larynx. 2010;37(3):286–90.PubMedCrossRefGoogle Scholar
  86. 86.
    Mijovic T, Zeitouni A, Colmegna I. Autoimmune sensorineural hearing loss: the otology-rheumatology interface. Rheumatology (Oxford). 2013;52(5):780–9.CrossRefGoogle Scholar
  87. 87.
    Elidan J, Levi H, Cohen E, BenEzra D. Effect of cyclosporine A on the hearing loss in Behcet’s disease. Ann Otol Rhinol Laryngol. 1991;100(6):464–8.PubMedCrossRefGoogle Scholar
  88. 88.
    Quaranta N, Bartoli R, Giagnotti F, Di Cuonzo F, Quaranta A. Cochlear implants in systemic autoimmune vasculitis syndromes. Acta Otolaryngol Suppl. 2002;(548):44–8.CrossRefGoogle Scholar
  89. 89.
    Szilvassy J, Czigner J, Jori J, Toth F, Szilvassy Z, Mieszkowski JM, et al. Cochlear implantation of a Hungarian deaf and blind patient with discharging ears suffering from Behçet’s disease. J Laryngol Otol. 1998;112(2):169–71.PubMedCrossRefGoogle Scholar
  90. 90.
    Barna BP, Hughes GB. Autoimmunity and otologic disease: clinical and experimental aspects. Clin Lab Med. 1988;8(2):385–98.PubMedCrossRefPubMedCentralGoogle Scholar
  91. 91.
    Akpolat T, Dilek M, Aksu K, Keser G, Toprak O, Cirit M, et al. Renal Behçet’s disease: an update. Semin Arthritis Rheum. 2008;38(3):241–8.PubMedCrossRefPubMedCentralGoogle Scholar
  92. 92.
    Cho SB, Kim J, Kang SW, Yoo TH, Zheng Z, Cho S, et al. Renal manifestations in 2007 Korean patients with Behcet’s disease. Yonsei Med J. 2013;54(1):189–96.PubMedCrossRefPubMedCentralGoogle Scholar
  93. 93.
    Kaklamani VG, Nikolopoulou N, Sotsiou F, Billis A, Kaklamanis P. Renal involvement in Adamantiades-Behçet’s disease. Case report and review of the literature. Clin Exp Rheumatol. 2001;19(5 Suppl 24):S55–8.PubMedPubMedCentralGoogle Scholar
  94. 94.
    Rosenthal T, Weiss P, Gafni J. Renal involvement in Behçet’s syndrome. Arch Intern Med. 1978;138(7):1122–4.PubMedCrossRefPubMedCentralGoogle Scholar
  95. 95.
    Zheng W, Li G, Zhou M, Chen L, Tian X, Zhang F. Renal involvement in Chinese patients with Behcet’s disease: a report of 16 cases. Int J Rheum Dis. 2015;18(8):892–7.PubMedCrossRefPubMedCentralGoogle Scholar
  96. 96.
    Akpolat T, Akkoyunlu M, Akpolat I, Dilek M, Odabas AR, Ozen S. Renal Behçet’s disease: a cumulative analysis. Semin Arthritis Rheum. 2002;31(5):317–37.PubMedCrossRefPubMedCentralGoogle Scholar
  97. 97.
    Akpolat T, Diri B, Oğuz Y, Yilmaz E, Yavuz M, Dilek M. Behçet’s disease and renal failure. Nephrol Dial Transplant. 2003;18(5):888–91.PubMedCrossRefPubMedCentralGoogle Scholar
  98. 98.
    Akpolat T, Yilmaz E, Akpolat I, Dilek M, Karagoz F, Balci B, et al. Amyloidosis in Behçet's disease and familial Mediterranean fever. Rheumatology (Oxford). 2002;41(5):592–3.CrossRefGoogle Scholar
  99. 99.
    Dilsen N, Konice M, Aral O, Erbengi T, Uysal V, Kocak N, et al. Ozdogan et’s disease associated with amyloidosis in Turkey and in the world. Ann Rheum Dis. 1988;47(SRC - BaiduScholar):157–63.PubMedPubMedCentralCrossRefGoogle Scholar
  100. 100.
    Melikoglu M, Altiparmak MR, Fresko I, Tunc R, Yurdakul S, Hamuryudan V, et al. A reappraisal of amyloidosis in Behçet’s syndrome. Rheumatology (Oxford). 2001;40(SRC - BaiduScholar):212–5.CrossRefGoogle Scholar
  101. 101.
    Yurdakul S, Tüzüner N, Yurdakul I, Hamuryudan V, Yazici H. Amyloidosis in Behçet’s syndrome. Arthritis Rheum. 1990;33(10):1586–9.PubMedCrossRefGoogle Scholar
  102. 102.
    Chiba M, Inoue Y, Arakawa H, Masamune O, Ohkubo M. Behçet’s disease associated with amyloidosis. Gastroenterol Jpn. 1987;22(4):487–95.PubMedCrossRefPubMedCentralGoogle Scholar
  103. 103.
    Erten S, Perçınel S, Olmez U, Ensarı A, Düzgün N. Behçet’s disease associated with diarrhea and secondary amyloidosis. Turk J Gastroenterol. 2011;22(1):106–7.PubMedCrossRefPubMedCentralGoogle Scholar
  104. 104.
    Sato S, Yashiro M, Matsuoka N, Kawana S, Asano T, Kobayashi H, et al. Behcet disease associated with gastrointestinal amyloidosis manifested as hematochezia: a case report. Medicine (Baltimore). 2018;97(26):e11153.CrossRefGoogle Scholar
  105. 105.
    Kosemehmetoglu K, Baydar DE. Renal amyloidosis in Behçet’s disease: clinicopathologic features of 8 cases. Int Urol Nephrol. 2013;45(3):785–94.PubMedCrossRefPubMedCentralGoogle Scholar
  106. 106.
    Rosenthal T, Bank H, Aladjem M, David R, Gafni J. Systemic amyloidosis in Behçet’s disease. Ann Intern Med. 1975;83(2):220–3.PubMedCrossRefGoogle Scholar
  107. 107.
    Utku U, Dilek M, Akpolat I, Bedir A, Akpolat T. SAA1 alpha/alpha alleles in Behçet’s disease related amyloidosis. Clin Rheumatol. 2007;26(6):927–9.PubMedCrossRefPubMedCentralGoogle Scholar
  108. 108.
    Tasdemir I, Sivri B, Turgan C, Emri S, Yasavul U, Caglar S. The expanding spectrum of a disease. Behçet’s disease associated with amyloidosis. Nephron. 1989;52(2):154–7.PubMedCrossRefGoogle Scholar
  109. 109.
    Bilginer Y, Ayaz NA, Ozen S. Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behçet’s disease. Clin Rheumatol. 2010;29(2):209–10.CrossRefGoogle Scholar
  110. 110.
    Ilbay A, Erden A, Sari A, Armagan B, Aktas BY, Bolek EC, et al. Successful treatment of amyloid A-type amyloidosis due to Behçet disease with Tocilizumab. J Clin Rheumatol. 2018;25(4):43.CrossRefGoogle Scholar
  111. 111.
    Altiparmak MR, Tanverdi M, Pamuk ON, Tunç R, Hamuryudan V. Glomerulonephritis in Behçet’s disease: report of seven cases and review of the literature. Clin Rheumatol. 2002;21(1):14–8.PubMedCrossRefGoogle Scholar
  112. 112.
    Gürler A, Boyvat A, Türsen U. Clinical manifestations of Behçet’s disease: an analysis of 2147 patients. Yonsei Med J. 1997;38(6):423–7.CrossRefGoogle Scholar
  113. 113.
    Kavala M, Menteş F, Kocaturk E, Ergin H, Zindanci I, Can B, et al. Microalbuminuria as an early marker of renal involvement in Behcet’s disease: it is associated with neurological involvement and duration of the disease. J Eur Acad Dermatol Venereol. 2010;24(7):840–3.PubMedCrossRefPubMedCentralGoogle Scholar
  114. 114.
    Finucane P, Doyle CT, Ferriss JB, Molloy M, Murnaghan D. Behçet’s syndrome with myositis and glomerulonephritis. Br J Rheumatol. 1985;24(4):372–5.PubMedCrossRefGoogle Scholar
  115. 115.
    Tietjen DP, Moore WJ. Treatment of rapidly progressive glomerulonephritis due to Behçet’s syndrome with intravenous cyclophosphamide. Nephron. 1990;55(1):69–73.PubMedCrossRefPubMedCentralGoogle Scholar
  116. 116.
    Kim HJ, Kang SW, Park SJ, Kim TH, Kang MS, Kim YH. Fibrillary glomerulonephritis associated with Behçet’s syndrome. Ren Fail. 2012;34(5):637–9.PubMedCrossRefPubMedCentralGoogle Scholar
  117. 117.
    Donnelly S, Jothy S, Barré P. Crescentic glomerulonephritis in Behçet’s syndrome--results of therapy and review of the literature. Clin Nephrol. 1989;31(4):213–8.PubMedGoogle Scholar
  118. 118.
    El Ramahi KM, Al Dalaan A, Al Shaikh A, Al Meshari K, Akhtar M. Renal involvement in Behçet’s disease: review of 9 cases. J Rheumatol. 1998;25(11):2254–60.PubMedGoogle Scholar
  119. 119.
    Fukuda T, Hayashi K, Sakamoto I, Mori M. Acute renal infarction caused by Behçet’s disease. Abdom Imaging. 1995;20(3):264–6.PubMedCrossRefGoogle Scholar
  120. 120.
    Sudo J, Matsubara T, Iwai H, Ueda Y, Kameda S, Iwata T, et al. IgA nephropathy developed in a patient with Behçet’s disease. Kidney Dial. 1987;22 SRC - BaiduScholar:893–7.Google Scholar
  121. 121.
    Sugiyama E, Suzuki H, Akagawa N, Yamashita N, Yano S, Iida H, et al. Behçet’s disease associated with IgA nephropathy: report of a case. Nippon Naika Gakkai Zasshi. 1984;73(12):1818–22.PubMedCrossRefGoogle Scholar
  122. 122.
    Hamuryudan V, Yurdakul S, Kural AR, Ince U, Yazici H. Diffuse proliferative glomerulonephritis in Behcet’s syndrome. Br J Rheumatol. 1991;30(1):63–4.PubMedCrossRefGoogle Scholar
  123. 123.
    Park SJ, Oh JY, Shin JI. Could increased IgA induced by BAFF be the cause of IgA nephropathy development in Behcet’s disease? Comment on: Behcet’s disease and IgA nephropathy (Rheumatol Int. 2012 Jul; 32(7):2227–9). Rheumatol Int. 2014;34(2):283–4.PubMedCrossRefGoogle Scholar
  124. 124.
    Oygar DD, Morris Y. Behçet’s disease and anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Intern Med. 2016;55(16):2225–8.PubMedCrossRefGoogle Scholar
  125. 125.
    Leonard D, Cortese C, Wadei HM, Porter Ii IE, Aslam N. Behcet’s syndrome and focal segmental glomerulosclerosis with nephrotic syndrome - successful treatment with etanercept. Clin Nephrol. 2018;89(5):371–5.PubMedCrossRefGoogle Scholar
  126. 126.
    Koç Y, Güllü I, Akpek G, Akpolat T, Kansu E, Kiraz S, et al. Vascular involvement in Behçet’s disease. J Rheumatol. 1992;19(3):402–10.PubMedGoogle Scholar
  127. 127.
    Sherif A, Stewart P, Mendes DM. The repetitive vascular catastrophes of Behçet’s disease: a case report with review of the literature. Ann Vasc Surg. 1992;6(1):85–9.PubMedCrossRefGoogle Scholar
  128. 128.
    Sueyoshi E, Sakamoto I, Hayashi N, Fukuda T, Matsunaga N, Hayashi K, et al. Ruptured renal artery aneurysm due to Behçet’s disease. Abdom Imaging. 1996;21(2):166–7.PubMedCrossRefGoogle Scholar
  129. 129.
    Han K, Siegel R, Pantuck AJ, Gazi MA, Burno DK, Weiss RE. Behcet’s syndrome with left ventricular aneurysm and ruptured renal artery pseudoaneurysm. Urology. 1999;54(1):162.PubMedCrossRefGoogle Scholar
  130. 130.
    Chen JY, Tsai YS, Li YH. Multiple arterial aneurysms in a patient with Behcet’s disease. Eur Heart J Cardiovasc Imaging. 2016;17(5):587.PubMedCrossRefGoogle Scholar
  131. 131.
    Batur A, Dorum M, Yuksekkaya HA, Koc O. Budd-chiari syndrome and renal arterial neurysms due to Behcet disease: a rare association. Pan Afr Med J. 2015;21:84.PubMedPubMedCentralCrossRefGoogle Scholar
  132. 132.
    Toprak O, Ersoy R, Uzum A, Memis A, Cirit M, Akpolat T. An unusual vascular involvement in a patient with Behcet’s disease: renal artery stenosis. Am J Med Sci. 2007;334(5):396–8.PubMedCrossRefGoogle Scholar
  133. 133.
    Malik GH, Sirwal IA, Pandit KA. Behcet’s syndrome associated with minimal change glomerulonephritis and renal vein thrombosis. Nephron. 1989;52(1):87–9.PubMedCrossRefGoogle Scholar
  134. 134.
    Angotti C, D’Cruz DP, Abbs IC, Hughes GRV. Renal microinfarction in Behçet’s disease. Rheumatology (Oxford). 2003;42(11):1416–7.CrossRefGoogle Scholar
  135. 135.
    Planer D, Verstandig A, Chajek-Shaul T. Transcatheter embolization of renal artery aneurysm in Behçet’s disease. Vasc Med. 2001;6(2):109–12.PubMedCrossRefGoogle Scholar
  136. 136.
    Ali O, Nicholl P, Carruthers D, Geoghegan J, Tiwari A. Multiple aneurysms and a transplanted kidney in Behçet disease. Vasc Endovasc Surg. 2017;51(2):108–10.CrossRefGoogle Scholar
  137. 137.
    Apaydin S, Erek E, Ulkü U, Hamuryudan V, Yazici H, Sariyar M. A successful renal transplantation in Behçet’s syndrome. Ann Rheum Dis. 1999;58(11):719.PubMedPubMedCentralCrossRefGoogle Scholar
  138. 138.
    Kirkali Z, Yigitbasi O, Sasmaz R. Urological aspects of Behçet’s disease. Br J Urol. 1991;67(6):638–9.PubMedCrossRefGoogle Scholar
  139. 139.
    Kanakis MA, Vaiopoulos AG, Vaiopoulos GA, Kaklamanis PG. Epididymo-Orchitis in Bechet’s disease: a review of the wide spectrum of the disease. Acta Med Iran. 2017;55(8):482–5.PubMedGoogle Scholar
  140. 140.
    Sharquie KE, Al-Rawi Z. Epididymo-orchitis in Behçets disease. Br J Rheumatol. 1987;26(6):468–9.PubMedCrossRefGoogle Scholar
  141. 141.
    Kaklamani VG, Vaiopoulos G, Markomichelakis N, Kaklamanis P. Recurrent epididymo-orchitis in patients with Behçet’s disease. J Urol. 2000;163(2):487–9.PubMedCrossRefGoogle Scholar
  142. 142.
    Callejas-Rubio JL, Ortego N, Díez A, Castro M, De La Higuera J. Recurrent epididymo-orchitis secondary to Behçets disease. J Urol. 1998;160(2):496.PubMedCrossRefPubMedCentralGoogle Scholar
  143. 143.
    Yilmaz O, Yilmaz S, Kisacik B, Aydogdu M, Bozkurt Y, Erdem H, et al. Varicocele and epididymitis in Behcet disease. J Ultrasound Med. 2011;30(7):909–13.PubMedCrossRefPubMedCentralGoogle Scholar
  144. 144.
    Pannek J, Haupt G. Orchitis due to vasculitis in autoimmune diseases. Scand J Rheumatol. 1997;26(3):151–4.PubMedCrossRefPubMedCentralGoogle Scholar
  145. 145.
    Eilber KS, Freedland SJ, Rajfer J. Polyarteritis nodosa presenting as hematuria and a testicular mass. J Urol. 2001;166(2):624.PubMedCrossRefPubMedCentralGoogle Scholar
  146. 146.
    Mayer DF, Matteson EL. Testicular involvement in rheumatoid vasculitis. Clin Exp Rheumatol. 2004;22(6 Suppl 36):S62–4.PubMedGoogle Scholar
  147. 147.
    Joudi FN, Austin JC, Vogelgesang SA, Jensen CS. Isolated testicular vasculitis presenting as a tumor-like lesion. J Urol. 2004;171(2 Pt 1):799.PubMedCrossRefGoogle Scholar
  148. 148.
    Yamashita C, Otsuka A, Dainichi T, Kabashima K. Novel MEFV variant Q311H in an incomplete Behçet’s disease patient with recurrent epididymitis. J Eur Acad Dermatol Venereol. 2016;30(11):e173–e4.PubMedGoogle Scholar
  149. 149.
    Ek L, Hedfors E. Behçet’s disease: a review and a report of 12 cases from Sweden. Acta Derm Venereol. 1993;73(4):251–4.PubMedPubMedCentralGoogle Scholar
  150. 150.
    Zouboulis CC, Kötter I, Djawari D, Kirch W, Kohl PK, Ochsendorf FR, et al. Epidemiological features of Adamantiades-Behçet’s disease in Germany and in Europe. Yonsei Med J. 1997;38(6):411–22.PubMedPubMedCentralCrossRefGoogle Scholar
  151. 151.
    Fuse H, Ohkawa M, Yamaguchi K, Hirata A, Matsubara F. Cryptococcal prostatitis in a patient with Behçet’s disease treated with fluconazole. Mycopathologia. 1995;130(3):147–50.PubMedCrossRefGoogle Scholar
  152. 152.
    Chajek T, Fainaru M. Behçet’s disease. Report of 41 cases and a review of the literature. Medicine. 1975;54(3):179–96.PubMedCrossRefGoogle Scholar
  153. 153.
    McDonald GS, Gad-Al-Rab J. Behçet’s disease with endocarditis and the Budd-Chiari syndrome. J Clin Pathol. 1980;33(7):660–9.PubMedPubMedCentralCrossRefGoogle Scholar
  154. 154.
    Ates A, Aydintug OT, Duzgun N, Yaman O, Sancak T, Omür ND. Omur et’s disease presenting as deep venous thrombosis and priapism. Clin Exp Rheumatol. 2004;22(1 SRC - BaiduScholar):107–9.PubMedGoogle Scholar
  155. 155.
    Moalla M, Gabsi M, el Ouakdi M, Zmerli S, Ben Ayed H. Behçet disease and priapism. J Rheumatol. 1990;17(4):570–1.PubMedGoogle Scholar
  156. 156.
    Beddouche A, Ouaziz H, Zougaghi S, Alaoui A, Dergamoun H, El Sayegh H, et al. Deep dorsal penile vein thrombosis revealing Behcet’s disease. Pan Afr Med J. 2016;24:17.PubMedPubMedCentralGoogle Scholar
  157. 157.
    Erdogru T, Kocak T, Serdaroglu P, Kadioglu AS, Taylan A, et al. Evaluation and therapeutic approaches of voiding and erectile dysfunction in neurological Behçet’s syndrome. Birlik neuroBehet disease with erectile dysfunction and micturition disturbances case report and literature review. Rheumatol Int. 38149152. 2018;162(1 SRC - BaiduScholar):147–53.Google Scholar
  158. 158.
    Taylan A, Birlik M. Parenchymal neuro-Behçet disease with erectile dysfunction and micturition disturbances: case report and literature review. Rheumatol Int. 2018;38(1):149–52.PubMedCrossRefGoogle Scholar
  159. 159.
    Kone-Paut I, Yurdakul S, Bahabri SAJ, et al. Clinical features of Behçet’s disease in children: an international collaborative study of 86 cases. 1998;132(4 SRC - BaiduScholar):721–5.Google Scholar
  160. 160.
    Shaefei N, Shahram F, Davatchi F, et al. Comparison of juvenile with adult Behçet’s disease (A). Arthritis Rheum. 1998;41(S124).Google Scholar
  161. 161.
    Pektas A, Devrim I, Besbas N, Bilginer Y, Cengiz AB, Ozen S. A child with Behcet’s disease presenting with a spectrum of inflammatory manifestations including epididymoorchitis. Turk J Pediatr. 2008;50(1):78–80.PubMedGoogle Scholar
  162. 162.
    Alizadeh F, Khorrami MH, Izadpanahi MH, Nouri-Mahdavi K, Mohammadi Sichani M. Bladder involvement in Behcet’s disease. Urol J. 2012;9(1):347–50.PubMedGoogle Scholar
  163. 163.
    Lakhanpal S, Tani K, Lie JT, Katoh K, Ishigatsubo Y, Ohokubo T. Pathologic features of Behçet’s syndrome: a review of Japanese autopsy registry data. Hum Pathol. 1985;16(8):790–5.PubMedCrossRefPubMedCentralGoogle Scholar
  164. 164.
    Dokmeci F, Cengiz BF. Ortac mass in a patient with Behçet’s disease. Obstet Gynecol 881. 1996;87(5 Pt 2 SRC - BaiduScholar).Google Scholar
  165. 165.
    Cetinel B, Akpinar H, Tüfek I, Uygun N, Solok V, Yazici H. Bladder involvement in Behçet’s syndrome. J Urol. 1999;161(1):52–6.PubMedCrossRefGoogle Scholar
  166. 166.
    Monteiro H, Nogueira RH, Akin Y, Yucel SJ, et al. de Carvalho et’s syndrome and vesicovaginal fistula: an unusual complication. An extremely rare manifestation of Behcets disease urethrovaginal fistula. Int Urol Nephrol. 4635961. 2014;153(2 SRC - BaiduScholar):407–8.Google Scholar
  167. 167.
    Akin Y, Yucel S, Baykara M. An extremely rare manifestation of Behcet’s disease: urethrovaginal fistula. Int Urol Nephrol. 2014;46(2):359–61.PubMedCrossRefGoogle Scholar
  168. 168.
    Aoki T, Tanaka T, Akifuji Y, Ueki J, Nakamura I, Nemoto R, et al. Beneficial effects of interferon-alpha in a case with Behçet’s disease. Intern Med. 2000;39(8):667–9.PubMedCrossRefGoogle Scholar
  169. 169.
    Cetinel B, Obek C, Solok V, Yaycioglu O, Yazici H. Urologic screening for men with Behçet’s syndrome. Urology. 1998;52(5):863–5.PubMedCrossRefGoogle Scholar
  170. 170.
    Saito M, Miyagawa I. Bladder dysfunction due to Behçet’s disease. Urol Int. 2000;65(1):40–2.PubMedCrossRefGoogle Scholar
  171. 171.
    Karandreas N, Tsivgoulis G, Zambelis T, Kokotis P, Rapidi A, Petropoulou K, et al. Urinary frequency in a case of Neuro-Behcet disease involving the brainstem - clinical, electrophysiological and urodynamic features. Clin Neurol Neurosurg. 2007;109(9):806–10.PubMedCrossRefGoogle Scholar
  172. 172.
    Akman-Demir G, Serdaroglu P, Tasçi B. Clinical patterns of neurological involvement in Behçet’s disease: evaluation of 200 patients. The Neuro-Behçet Study Group. Brain. 1999;122(Pt 11):2171–82.CrossRefGoogle Scholar
  173. 173.
    Yesilot N, Mutlu M, Gungor O, Baykal B, Serdaroglu P, Akman-Demir G. Clinical characteristics and course of spinal cord involvement in Behçet’s disease. Eur J Neurol. 2007;14(7):729–37.PubMedCrossRefGoogle Scholar
  174. 174.
    Szymajda A, Eledrisi MS, Patel R, Chaljub G, Cepeda E, Kaushik P. Diabetes insipidus as a consequence of neurologic involvement in Behcet’s syndrome. Endocr Pract. 2003;9(1):33–5.PubMedCrossRefGoogle Scholar
  175. 175.
    Jin-No M, Fujii T, Jin-No Y, Kamiya Y, Okada M, Kawaguchi M. Central diabetes insipidus with Behçet’s disease. Intern Med. 1999;38(12):995–9.PubMedCrossRefPubMedCentralGoogle Scholar
  176. 176.
    Theodorou C, Floratos D, Hatzinicolaou P, Vaiopoulos G. Neurogenic bladder dysfunction due to Behçet’s disease. Int J Urol. 1999;6(8):423–5.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of Medicine, Division of RheumatologyNew York University School of MedicineNew YorkUSA
  2. 2.Department of Internal Medicine, Division of RheumatologyCerrahpasa Medical FacultyIstanbulTurkey

Personalised recommendations